Tags : Start Codon


Spirea secures Seed investment led by Meltwind and Start Codon

Spirea completes seed funding round to develop the next generation of antibody-drug conjugate therapeutics Spirea, a spin-out from the University of Cambridge, has developed a novel antibody-drug conjugate platform and aims to reshape the future of cancer treatment Spirea’s flexible technology achieves a high and stable drug-to-antibody ratio resulting in an improved therapeutic index to […]Read More